{"id":620,"date":"2024-07-01T16:16:23","date_gmt":"2024-07-01T16:16:23","guid":{"rendered":"https:\/\/gimm.pt\/spinoffs\/limm\/"},"modified":"2024-07-08T15:29:19","modified_gmt":"2024-07-08T15:29:19","slug":"limm","status":"publish","type":"spinoffs","link":"https:\/\/gimm.pt\/pt-pt\/spinoffs\/limm\/","title":{"rendered":"LiMM"},"content":{"rendered":"\n<p><br\/>A LiMM \u00e9 a empresa biofarmac\u00eautica que explora a intera\u00e7\u00e3o molecular entre as c\u00e9lulas neuronais e as c\u00e9lulas linf\u00f3ides inatas nos tecidos perif\u00e9ricos. Ao descodificar a linguagem do di\u00e1logo neuro-imune, estamos a desenvolver produtos terap\u00eauticos de primeira classe &#8211; NRILs: reprogramadores neuronais de linf\u00f3citos inatos &#8211; para preservar a sa\u00fade e tratar doen\u00e7as inflamat\u00f3rias, infecciosas e metab\u00f3licas. Estamos a fazer a ponte entre a dete\u00e7\u00e3o neural e as descobertas da imunologia para desbloquear solu\u00e7\u00f5es terap\u00eauticas em benef\u00edcio dos doentes.<\/p>\n\n<p><strong>DIRECTOR EXECUTIVO:<\/strong> David Malta<\/p>\n\n<p><strong>CSO:<\/strong> Henrique Veiga Fernandes<\/p>\n","protected":false},"featured_media":704,"template":"","acf":[],"_links":{"self":[{"href":"https:\/\/gimm.pt\/pt-pt\/wp-json\/wp\/v2\/spinoffs\/620"}],"collection":[{"href":"https:\/\/gimm.pt\/pt-pt\/wp-json\/wp\/v2\/spinoffs"}],"about":[{"href":"https:\/\/gimm.pt\/pt-pt\/wp-json\/wp\/v2\/types\/spinoffs"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/gimm.pt\/pt-pt\/wp-json\/wp\/v2\/media\/704"}],"wp:attachment":[{"href":"https:\/\/gimm.pt\/pt-pt\/wp-json\/wp\/v2\/media?parent=620"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}